2025 marked a robust year for initial public offerings (IPOs) within the United States, fueled by a more relaxed stance from the Federal Reserve. Numerous companies across diverse sectors successfully launched their shares on the market, including the AI infrastructure firm Coreweave (CRWV), the design powerhouse Figma (FIG), and the stablecoin issuer Circle (CRCL). Investors responded favorably, as evidenced by a model portfolio of all U.S. IPOs through June 2025 generating a remarkable 75.9% return, substantially outperforming the S&P 500’s 4.9% gains. This strong performance was driven by significant activity in the artificial intelligence and fintech sectors. Notably, one of the largest IPOs of the year landed in the final months, further bolstering the market’s momentum.
The initial public offering of Medline (MDLN) exemplified this year’s strong IPO performance. The company, a major healthcare and medical-surgical products manufacturer and distributor, successfully generated $6.26 billion through the sale of 216 million shares at $29 each – an upsize from its initial plan to offer 179 million shares in the range of $26 to $30. The stock’s debut was exceptionally strong, experiencing a 41% rally from its issue price. Proceeds from the offering were strategically allocated to reduce existing debt and for general corporate purposes. However, as market enthusiasm surrounding the IPO waned, investors began to assess the long-term investment potential of MDLN stock.
Medline boasts a substantial operational footprint and a compelling value proposition. The company operates through two primary business segments: the Medline brand, which manufactures proprietary medical products such as surgical kits, gloves, and gowns, and its supply chain solutions business, providing distribution and logistics services to hospitals, surgery centers, physician offices, nursing homes, and other care facilities. The company’s scale is particularly impressive, serving a global customer base of approximately 100 countries from its 33 manufacturing facilities across 28 million square feet. This extensive network allows Medline to maintain a direct control over specifications, rework, and product introductions – a critical advantage that minimizes reliance on external OEM lead times and drives cost efficiencies. Furthermore, the company’s nearly flawless track record of next-day delivery to approximately 95% of U.S. customers, coupled with high prime-vendor retention rates (>98%), ensures predictable recurring revenue streams. This commitment directly benefits its customers by minimizing clinical interruptions.
Despite the company’s robust short-term debt levels — standing at $580 million at the close of June 2025 — a significant long-term debt burden remained, totaling approximately $13 billion following the IPO. While interest payments on this debt represent an average annual expense of around $200 million, Medline’s strong operating performance significantly covers this obligation. With revenues consistently exceeding $20 billion and a quarterly operating income averaging over $600 million, the company maintains a strong financial position. Ultimately, Medline’s substantial scale, established competitive advantage, and global distribution network position it as a leading player within the healthcare and medical-surgical products industry, suggesting a solid investment opportunity. Pathikrit Bose did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
